Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of a specific transaction rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the GSK 401K plan. This resulted in an increase in the notional allocation of American Depositary Shares (ADSs) on July 7, 2014, at a price of $54.11 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Important Facts for Investors
- Transaction Date: July 7, 2014.
- Transaction Price: $54.11 per ADS.
- Beneficiary: Dr. K. Slaoui (Connected Person of Director Dr. M. Slaoui).
- Volume: 4 ADSs allocated to the connected person.
- Director Allocation: Dr. M. Slaoui received 0 ADSs in this specific transaction.